Revolution Medicines, Inc. RVMD

Revolution Medicines (RVMD) is expected to have a "strong" launch for its Rasonque drug in second-li

Equity Insider News Commentary - For most of the last four decades, RAS was the target oncology could not hit. That has changed quickly, and the commercial numbers are starting to follow. According to DelveInsight, the KRAS inhibitors market across the seven major markets was valued at approximately $526 million in 2025 and is projected to reach approximately $7.85 billion by 2034, a compound annual growth rate of roughly 35% over its 2024 to 2034 forecast period, with the United States expected

Pre-commercial precision oncology firms often face steep financial trade-offs, where absent return on invested capital/ROIC and negative operating cash flows are the price of admission for long-term clinical innovation. IDEAYA Biosciences (NASDAQ:IDYA) operates from a position of relative balance sheet strength, backed by $1.24 billion in cash, cash equivalents, and marketable securities that extend its […]

Revolution Medicines (RVMD) just picked up Breakthrough Therapy Designation from the FDA for RASONQUE in treatment naïve metastatic pancreatic adenocarcinoma, a cancer setting with limited options and intense clinical interest. That regulatory progress is landing against a mixed tape for Revolution Medicines, with the share price easing 5.9% over the past week and 7.9% over the past month, yet still showing strong momentum overall through a 13.6% 3 month share price return and a very large 1...

Earlier in September 2026, Revolution Medicines announced that the FDA granted Breakthrough Therapy Designation to RASONQUE (daraxonrasib) plus chemotherapy for treatment‑naïve metastatic pancreatic adenocarcinoma, adding to its existing U.S. approval in later‑line PDAC. The company was also added to the FTSE All‑World Index (USD), potentially broadening its shareholder base as it advances a late‑stage RAS(ON) pipeline in a cancer with very limited treatment options. With Breakthrough...

Revolution Medicines (NasdaqGS: RVMD) received FDA Breakthrough Therapy Designation for RASONQUE (daraxonrasib) in metastatic pancreatic adenocarcinoma. The designation covers RASONQUE in combination with existing chemotherapy for patients who have not previously received treatment. Breakthrough Therapy status may provide access to expedited FDA interactions and review processes for this treatment candidate. The Breakthrough Therapy Designation for RASONQUE in first line metastatic...

Company CEO outlines the differentiated mechanism and clinical potential of Ampligen in pancreatic cancer Survival data highlighted in accompanying chart show Ampligen-associated median overall survival of 34.8 months in a selected pancreatic patient population versus 12.5 months in historical controls OCALA, Fla., Sept. 22, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today issued a letter to stockholders from Chief Executive Officer Thomas Equels a

New Preclinical PDAC Package for PRP Shows >90% Tumor-Growth Inhibition & >2.5-Fold Survival Benefit; Company Contrasts Mechanism, Breadth, & Development Role Against Erasca’s Phase 1 ERAS-0015 Dataset MELBOURNE, Australia, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today issued a comparative analysis of l

Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” second-quarter 2026 investor letter. The letter can be downloaded here. During the quarter, the Fund (Investor Shares) returned 17.49% (net of fees), outperforming the Russell 1000 Growth Index’s 16.74%. Holdings in Information Technology and Consumer Discretionary sectors boosted relative returns, while Communication Services […]

New Preclinical PDAC Data for PRP Show >90% Tumor-Growth Inhibition & >2.5-Fold Survival Benefit; Company Highlights How Reversing Epithelial-Mesenchymal Transition May Deepen & Extend Responses to RAS(ON) & Pan-RAS TherapiesMELBOURNE, Australia, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today issued a co

Company receives third Breakthrough Therapy Designation for RASONQUE and fifth across its portfolio of RAS(ON) inhibitors, further highlighting its differentiated strategy for developing innovative medicines for patients with RAS-addicted cancers REDWOOD CITY, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cance

Stocks fell this week on oil prices and Fed rate-hike expectations, though Oracle's earnings underscored AI infrastructure strength. MarketBeat analysts recap top stories on earnings, defense, AI, and other stock opportunities.

Reuters reported that the FDA approved Revolution Medicines, Inc. (NASDAQ:RVMD) Rasonque (daraxonrasib) on August 26 for adults with metastatic pancreatic cancer who have already received prior treatment or cannot receive combination chemotherapy. The once-daily pill is the first broad RAS-targeted medicine approved for pancreatic cancer, designed to block several forms of the RAS protein that […]

Fresh off a regulatory victory for its groundbreaking cancer drug, Revolution Medicines could capture even more of the oncology market.